Hoffmann-La Roche Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

F. Hoffmann-La Roche Ag

Sabine Imhof-Jung

Christian Klein

Wolfgang Schaefer

Joerg Thomas Regula

Michael Molhoj

Juergen Michael Schanzer

Pablo Umana

Guy Georges

Hubert Kettenberger

Petra Rueger

Harald Duerr

Sebastian Fenn

Ulrich Goepfert

Marina Bacac

Stefan Klostermann

Laurent Lariviere

Stefan Seeber

Ulrich Brinkmann

Anita Kavlie

Oliver Ast

Monika Baehner

Christiane Neumann

Stefan Dengl

Guido Hartmann

Roland Beckmann

Remko Griep

Ekkehard Moessner

Olaf Mundigl

Jens Fischer

Kristian Hobolt Jensen

Christian Schantz

Joerg Benz

Maria Amann

Ira H Pastan

Erhard Kopetzki

Pablo Umaña

Kay-Gunnar Stubenrauch

Stephan Fischer

Peter Bruenker

Markus Thomas

Werner Scheuer

Joerg Moelleken

Peter Michael Huelsmann

Christian Gassner

Stefan Lorenz

Barbara Weiser

Tilman Schlothauer

Claudia Ferrara Koller

Sandra Grau-Richards

Hendrik Knoetgen

Byungkook Lee

Gerhard Niederfellner

Masanori Onda

Friederike Hesse

Thomas Friess

Claudio Sustmann

Alexander Haas

Tanja Fauti

Alexander Bujotzek

Sylvia Herter

Maximiliane Koenig

Roland Staack

Johannes Sam

Laura Codarri Deak

Mario Perro

Adrian Zwick

Joerg Zielonka

Ronit Mazor

Christiane Jaeger

Laurene Pousse

Thomas Kraft

Estelle Marrer-Berger

Joerg Thomas

Janina Speck

Kristian Hobolt-Jensen

Christoph Ullmer

Juergen Peter Bachl

Carina Cantrill

Janine Faigle

Dietrich Tuerck

Reto Flury

Martina Schmittnaegel

Ben-Fillippo Krippendorff

Patrick Alexander Aaron Weber

Remko Albert Griep

Jörg Thomas Regula

Jürgen Michael Schanzer

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

Bispecific 2+1 contorsbodies

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Antibody that binds to VEGF and IL-1beta and methods of use

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules targeting OX40 and FAP

The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.

Antibody that binds to VEGF-A and ANG2 and methods of use

The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antigen binding proteins

The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specifically binding to PD1 and LAG3

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

Growing community of inventors

Planegg, Germany

Sabine Imhof-Jung